Home / People / Stefan-Ulrich Müller
Portrait ofStefan-Ulrich Müller

Stefan-Ulrich Müller, M. Jur. (Oxford)

Partner
Rechtsanwalt

CMS Hasche Sigle
Nymphenburger Straße 12
80335 Munich
Germany
Languages German, English

Stefan-Ulrich Müller specialises in domestic and cross-border venture capital, growth capital and M&A transactions. He advises financial investors, strategic investors as well as tech companies and management teams throughout the whole process from investment to exit. His practice – which clients highly recommend in various legal industry publications – in particular includes advising on investments and rounds of financing, corporate governance, venture debt as well as on the sale or IPO of the company. He also advises frequently on management and employee participations.

Stefan has special sector expertise in biotech and medtech and also with software and ecommerce companies.

He advises selected start-ups through the CMS equIP programme.

He joined CMS in 1995 and became a partner in 2000. Jointly with Jörg Zätzsch, he heads the CMS “Venture Capital Excellence Cluster“.

more less

Führender Name für Venture Capital

JUVE Handbuch, 2023/2024

„sehr saubere, effiziente und zielführende Arbeit“, Mandant; „sehr kompetent und sehr sorgfältig“, Wettbewerber

JUVE Handbuch, 2023/2024

„Oft empfohlen“ für Private Equity und Venture Capital

JUVE Handbuch, 2023/2024

Listed as leading individual

Chambers Europe, 2023

Listed for Venture Capital

Deutschlands beste Anwälte 2023 – Handelsblatt in Kooperation mit Best Lawyers

Hall of Fame for Venture Capital

The Legal 500 EMEA, 2023

"highly competent and thorough", competitor

JUVE German Commercial Law Firms 2022 (GCLF)

"Recommended" for Private Equity and Venture Capital

JUVE German Commercial Law Firms 2022 (GCLF)

Listed as notable practitioner

Chambers Europe, 2021

Leading individual for Venture capital

The Legal 500 EMEA, 2027

"has built up a large VC team in Munich", competitor

JUVE German Commercial Law Firms 2021 (GCLF)

"Recommended" for Private Equity and Venture Capital

JUVE German Commercial Law Firms 2021 (GCLF)

"He always finds a very creative solution and good compromise suggestions. He is very calm and composed."

Chambers Europe, 2019

Listed as Leading Individual

Chambers Europe, 2022

Listed as notable practitioner

Chambers Europe, 2022

Hall of Fame for Venture Capital

The Legal 500 EMEA, 2022

Relevant experience

Investments

  • 2015: Advising LSP Life Sciences Partners on their investment in Luxendo
  • 2015: Advising Outfittery on USD 20 million round of financing
  • 2015: Advising Forbion Capital Partners and Sunstone Life Science Ventures on their investment in Rigontec
  • 2014: Advising invendo medical on EUR 20 million round of financing
  • 2014: Advising eGym on USD 15 million round of financing
  • 2013: Advising Immatics Biotechnologies on EUR 34 million investment round

Trade sales

  • 2015: Advising Earlybird Venture Capital and founders on the sale of carpooling.com to BlaBlaCar
  • 2015: Advising MIG, BioMedInvest and BayernKapital, among others on the sale of SuppreMol to Baxter; volume: EUR 200 million
  • 2014: Advising Gilde Healthcare on the sale of Definiens to MedImmune/AstraZeneca; volume: USD 150 million upfront plus milestone payments
  • 2014: Advising Sapiens Steering Brain Stimulation in the context of its sale to Medtronic; volume: EUR 150 million

IPOs

  • 2015: Advising Curetis on Euronext Amsterdam/Brussels IPO, including pre-IPO financing
  • 2014: Advising Affimed on Nasdaq Global Market IPO, including pre-IPO financing and venture debt

more less

Education

  • 1996: Magister Juris in European and Comparative Law, Magdalen College, University of Oxford
  • 1992 - 1994: Research assistant of Prof. Dr. Claus-Wilhelm Canaris at the Institute of Civil Law and Civil Procedure Law of the University of Munich
  • Trainee lawyer in the Higher Regional Court of Munich district
  • Law studies at the University of Munich and the University of Oxford
more less

Feed

26/03/2024
CMS advises sellers of Cardior Pharmaceuticals on potential acquisition...
Munich – CMS advises the sellers of Cardior Pharmaceuticals in the potential acquisition of the company by Novo Nordisk. Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved. The agreement includes Cardior’s lead compound CDR132L, currently in phase 2 clinical development for the treatment of heart failure. The closing of the acquisition is subject to receipt of applicable regulatory approvals and other customary conditions. It is expected to happen in the second quarter of 2024.A CMS team headed by Lead Partners Stefan-Ulrich Müller, Dr Tilman Weichert and Jörg Schrade advised the sellers of Cardior Pharmaceuticals on all legal aspects of the transaction. Cardior Pharmaceuticals GmbH, based in Hannover, Germany, is a leading clinical-stage bio­phar­ma­ceut­ic­al company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. CMS Germany Stefan-Ulrich Müller, Lead Partner Dr Tilman Weichert, Lead Partner Dr Michael Wangemann, Partner Dr Kai Wallisch, Partner Dr Thomas Mühl, Principal Coun­sel Se­basti­an Hummel, Senior As­so­ci­ate Vikt­or­ia Barthel, Senior As­so­ci­ate Mar­i­elouise Emmer, Senior Associate Dr Carl-Friedrich Thoma, Senior Associate Dr Stefan Kühl, Senior Associate Dr Alexander Weinhold, Senior Associate Maria Kucher, Associate Jonas Ohmann, Associate Dr Josephine Doll, Associate Dr Christian Seeburger, Associate Sonja Schanze, Associate, all Corporate/M&A Dr Marie-Luisa Loheide, Associate, Private Clients Jörg Schrade, Lead Partner Eduard Kosavtsev, Senior Associate, both Tax Stefan Lehr, Partner, Antitrust, Competition & Trade Stefan Lüft, Partner, IP Dr Benedikt Forschner, Partner, Labor, Employment & Pensions Dr Markus Kaulartz, Partner Dr Fiona Savary, Counsel Dr Felix Glocker, Senior Associate, all TMC Dr Tilman Niedermaier, Partner Susanne Schwalb, Partner, both Dispute ResolutionPress Con­tact presse@cms-hs. com
18/03/2024
CMS advises biotechnology firm Tubulis on EUR 128 million Series B2 financing...
Munich – Munich-based biotech company Tubulis has announced the successful completion of its extended and over-subscribed Series B2 round of financing, which raised EUR 128 million. This latest round was led by EQT Life Sciences and Swiss biotech investor Nextech Invest Ltd., representing funds that it manages. Other investors included US funds Frazier Life Sciences and Deep Track Capital along with all the existing investors, including Andera Partners, BioMedPartners, Fund+, Bayern Kapital’s ScaleUp-Fonds Bayern, Evotec, coparion, Seventure Partners, Occident and High-Tech Gründerfonds (HTGF). Tubulis will use the capital raised to develop the firm’s pipeline of next-generation antibody-drug conjugates (ADCs). The aim is also to complete the first clinical evaluation of its two drug candidates and to drive forward the company’s planned US expansion.A CMS team headed by partner Stefan-Ulrich Müller advised Tubulis on all legal aspects of the Series B2 financing. The team led by Stefan-Ulrich Müller has been advising Tubulis for several years now, including on the preceding EUR 60 million Series B round of financing. This work is another excellent example of the wide-ranging advisory services that CMS offers in the Lifesciences & Healthcare sector. CMS Germany Stefan-Ulrich Müller, Lead Part­ner Se­basti­an Hummel, Senior Associate Maria Kucher, Associate, all Corporate/M&A, Venture Capital Stefan Lüft, Partner, Intellectual Property Jörg Schrade, Partner, Tax Stefan Lehr, Partner, Antitrust, Competition & TradePress Con­tact presse@cms-hs. com
21/02/2024
CMS advises MVZ Laaff on sale to amedes
Stuttgart – The founder of medical laboratory MVZ Laaff, Prof. Helmut Laaff, has sold MVZ Laaff GmbH with its facilities in Freiburg, Heilbronn and Ulm to the amedes Group. amedes is a leading German lab services provider, operating a number of healthcare centres throughout Germany with different specialisations. MVZ Laaff provides services in fields of medicine including derma­to­path­o­logy, general pathology, immunohistology, molecular pathology and cytology, and is one of the leading laboratories in these specialist areas. Details of the transaction were not disclosed.A CMS team headed by lead partner Dr Christoph Lächler advised Prof. Helmut Laaff on all legal aspects of the transaction. The sale took place by way of an auction process. A particular focus of the advice was on structuring the transaction and the associated regulatory issues. CMS Germany Dr Christoph Lächler, Lead Part­ner Stefan-Ul­rich Müller, Partner Dr Jacob Siebert, Partner Viktoria Barthel, Senior Associate Tobias Kalski, Senior As­so­ci­ate An­dreas Kazmaier, Associate, all Corporate/M&A Dr Roland Wiring, Partner Dr Siham Hidar, Senior Associate, both Regulatory Dr Harald Kahlenberg, Partner Angelika Wieczorkowski, Senior Associate, both Antitrust, Competition & Trade Dr Stefan Voss, Partner Lukas Potstada, Counsel, both Real Estate Dr Martin Mohr, Partner, TaxPress Con­tact presse@cms-hs. com
06/07/2023
CMS advises fitness technology provider EGYM on €207 million comprehensive...
Munich – German fitness technology and corporate fitness provider EGYM has received €207 million in fresh capital from US investor Affinity Partners and existing investors Mayfair Equity Partners...
24/02/2023
CMS advises shareholders of Factor Eleven on their Exit to Armira
Munich – Factor Eleven, a leading digital marketing software company, announces a strategic collaboration with Armira, an investment holding company focused on family businesses and tech­no­logy. The...
20/06/2022
CMS advises Treasury Intelligence Solutions on the acquisition of Cashforce
Munich – Treasury Intelligence Solutions (TIS) acquires Cashforce, a Belgium-based FinTech start-up offering AI-based cash management and cash forecasting solutions. The acquisition of Cashforce is...
03/05/2022
CMS advises biotechnology firm Tubulis on EUR 60 million Series B financing...
Munich – Biotech company Tubulis has successfully completed a Series B round of financing worth EUR 60 million. Three new investors, Andera Partners, Evotec SE and Fund+, joined the round. All the existing...
28/04/2022
CMS advises sports-tech-com­pany EGYM on acquisition of Gymlib
Munich – The German fitness technology and corporate fitness provider EGYM acquires French competitor Gymlib. With the acquisition, the Munich-based sports-tech-com­pany aims for the market leadership...
03/03/2022
CMS advises digital health start-up Exakt Health on USD 1.5 million Series...
Munich / Frankfurt/Main – Berlin-based digital health start-up Exakt Health has received USD 1.5 million of new capital in a Series Pre-Seed round of financing to boost development of its physio­ther­ap­ist...
20/09/2021
EGYM completes successful USD 41 million round of financing with CMS support
Munich – Munich-based fitness tech start-up EGYM has raised USD 41 million in a Series E round of financing. The round saw Mayfair Equity Partners, a leading growth investor in the technology and consumer...
15/09/2021
CMS advises Sirion Biotech shareholders on acquisition by PerkinElmer
Munich – Listed US company PerkinElmer, Inc. has acquired SIRION BIOTECH, a leading global provider of viral vector-based technologies for cell and gene therapies. Sirion has established a strong portfolio...
25/08/2021
CMS advises biotech company Cardior Pharmaceuticals on EUR 64 million Series...
Munich – Cardior Pharmaceuticals GmbH, a biotech firm headquartered in Hanover, has raised around EUR 64 million in a Series B round of financing. Cardior develops non-coding RNA (ncRNA)-based therapeutics...